Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.285
+0.025 (0.77%)
Nov 5, 2024, 1:24 PM EST - Market open

Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.

It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.

Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 76
CEO Alexander Sapir

Contact Details

Address:
26 Landsdowne Street
Cambridge, Massachusetts 02139
United States
Phone 617 651 8851
Website fulcrumtx.com

Stock Details

Ticker Symbol FULC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001680581
CUSIP Number 359616109
ISIN Number US3596161097
Employer ID 47-4839948
SIC Code 2834

Key Executives

Name Position
Alexander C. Sapir Chief Executive Officer, President and Director
Alan A. Musso C.M.A., CPA Chief Financial Officer
Curtis G. Oltmans J.D. Senior Vice President, Chief Legal Officer and Corporate Secretary
Mel Hayes Executive Vice President of Patient Experience
Dr. Bradley E. Bernstein M.D., Ph.D. Founder
Dr. Michael R. Green Founder
Dr. Rudolf Jaenisch M.D., Ph.D. Founder
Dr. Tsun-Huei Lee M.D., Ph.D. Founder
Dr. Danny Reinberg Founder
Gregory Tourangeau Controller and Principal Accounting Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 24, 2024 8-K Current Report
Sep 20, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 12, 2024 8-K Current Report
Aug 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 22, 2024 8-K Current Report
Jul 31, 2024 S-8 Securities to be offered to employees in employee benefit plans